Skip Navigation
Skip to contents

Clin Endosc : Clinical Endoscopy

OPEN ACCESS

Articles

Page Path
HOME > Clin Endosc > Ahead-of print articles > Article
Review Hemostatic powder for gastrointestinal malignant tumor bleeding
Thanrada Vimonsuntirungsriorcid, Rapat Pittayanonorcid

DOI: https://doi.org/10.5946/ce.2025.387
Published online: March 25, 2026

Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Correspondence: Rapat Pittayanon Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama IV Road, Pathumwan, Bangkok 10330, Thailand E-mail: rapat.p@chula.ac.th
• Received: October 21, 2025   • Revised: December 18, 2025   • Accepted: December 20, 2025

© 2026 Korean Society of Gastrointestinal Endoscopy

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 2,957 Views
  • 329 Download
  • Gastrointestinal (GI) tumor bleeding remains a major clinical challenge worldwide, particularly for endoscopists. GI malignant tumor bleeding is uniquely characterized by diffuse oozing and friable tissue, which is vulnerable to further injury. This poses inherent limitations to conventional endoscopic treatments, resulting in low immediate hemostasis rates and a high risk of rebleeding. Traditional salvage surgery or embolization is the rescue treatment; however, they carry a higher mortality risk in the absence of stabilization. Importantly, survival in these patients depends on definitive oncological therapy, and endoscopic hemostasis is an essential frontline approach as a critical bridge to subsequent tumor treatment. Over the past decade, hemostatic powder has evolved into a promising treatment for malignant GI bleeding, distinguished by its ability to provide broad mucosal coverage through non-contact application. To date, adequately powered randomized controlled trials and meta-analyses have demonstrated superior immediate hemostasis and lower rebleeding rates with only a hemostatic powder agent (TC-325) over conventional endoscopic therapy. Thus, the efficacy of other hemostatic powder agents needs to be explored. To date, no luminal or systemic adverse events have been reported in studies on malignant bleeding, reassuring the safety of hemostatic powder in this setting.
Although the epidemiological shift toward tumor-related gastrointestinal (GI) bleeding has increased by 50% in the past decade,1 there is still no conclusive standard endoscopic treatment for GI tumor bleeding.2 Conventional endoscopic hemostatic methods, including coaptation therapy, argon plasma coagulation, and mechanical hemostasis, achieve suboptimal immediate success (31%3–68.6%4), with high short-term rebleeding rates of up to 80%.3 Salvage non-endoscopic treatments, such as surgery, embolization, and radiotherapy, have traditionally been employed, achieving higher hemostatic success rates of 50–100% and lower rebleeding rates of 0%–18%.5-7 Importantly, the mortality rate is higher in patients who undergo emergency surgery in an unstable condition.8 The use of hemostatic powder as a bridging endoscopic therapy to achieve immediate hemostasis until definitive oncological therapy is crucial.9 To date, a large randomized controlled trial (RCT)4 and meta-analyses,10,11 including individual patient data meta-analysis,11 have demonstrated a favorable immediate hemostasis success rate4,10-12 and acceptable rebleeding in the hemostatic powder group.4,11 Accordingly, the most recent 2025 guideline2 suggests hemostatic powder over conventional endoscopic therapy as the preferred hemostatic modality for active bleeding from malignant upper GI tumors. This review focuses on the evidence-based role of hemostatic powder in the management of GI malignant tumor bleeding, including its efficacy, safety, and feasibility, and provides practical tips and techniques for its effective application.
GI tumors account for up to 5% of upper GI bleeding13 and 3% to 11% of lower GI bleeding.14 Based on the nature and characteristics of malignant tumor bleeding, 77% of patients with GI malignancies initially presented with GI bleeding.15 Nearly half (40%) showed active bleeding (blood oozing [33%] and visible vessel [7%]) at the time of endoscopy.15
Hemostatic powder has been introduced over the past decade as a topical endoscopic agent for various etiologies of GI bleeding, with its initial use primarily in ulcer bleeding16,17 and variceal bleeding.18 Originating as a battlefield agent for bleeding control in combat injuries, hemostatic powder has since evolved into a mainstay bridging tool against GI malignancy-related bleeding worldwide.19
The main mechanism of bleeding is from the raw surface of the tumor or malignancy.15,20 A retrospective study of 42 patients with GI tumor bleeding showed that the most common cause of bleeding was from ulceration on the tumor (18/42, 42.9%).15 Moreover, unique physiological features, including progressive local vessel invasion, friable neovascularization of tumors, and underlying coagulopathy, worsen the bleeding.3,15,21 The diffuse nature of tumor bleeding results in the absence of a clear target, and friable tumor mucosa is unsuitable for tissue-traumatizing conventional endoscopic treatments, such as thermal, injection, or mechanical modalities, for effective hemostasis.3,4,21 Conventional endoscopic hemostatic methods have generally shown unfavorable immediate hemostatic success rates (31%–68.6%)3,4 with high rebleeding rates of up to 80%.3 Hemostatic powder provides broader surface coverage and non-contact application without the need for an en face view of the lesion, helping to overcome the challenges of endoscopic hemostasis in tumor bleeding.3
Four commercially available hemostatic powder agents were studied for tumor-related bleeding. First, inorganic mineral powder such as TC-325 (Hemospray; Cook Medical) are composed of bentonite mineral, which rapidly absorbs water, forming a cohesive barrier over the bleeding surfaces,20 and concentrating coagulation factors.22 Second, polymer-based powder such as UI-EWD (NexPowder; NextBiomedical Co., Ltd.) made from biocompatible polymers and Polysaccharide Hemostatic System (EndoClot Plus) made from modified starch forms an adhesive hydrogel in the presence of water to strongly adhere to mucosa and resists wash-off.23 The main mechanism of all three agents is the formation of a physical cohesive barrier that enables a mechanical tamponade effect for immediate hemostasis and prevents further acid-induced epithelial injury, thereby promoting mucosal healing.19,20 Its enhancing effects on local coagulation cascades allow prolonged hemostasis, despite detachment occurring mostly after 24 to 72 hours.9,23,24 Finally, plant-derived powder such as Ankaferd Blood Stopper (ABS; Ankaferd Health Products) creates an encapsulated protein network that promotes erythrocyte aggregation while attenuating fibrinolysis and anticoagulant pathways.25
Over the past decade, Chen et al.26 reported the successful application of TC-325 hemostatic powder in five cases of tumor-related upper GI bleeding and then Pittayanon et al.20 published the first comparative study of the efficacy of TC-325 as a first-line treatment for active tumor-related upper GI bleeding and conventional endoscopic treatment, showing a trend toward lower 14-day rebleeding rates (10% vs. 30%, p=0.6). Subsequently, growing evidence supports its clinical utility in tumor-related GI bleeding.
Based on efficacy, a pilot RCT by Chen et al.27 demonstrated the potential of TC-325 to achieve successful hemostasis over conventional endoscopic therapy in GI bleeding from tumors (90%, 9/10 vs. 40%, 4/10). However, insufficient evidence at that time limited the ability of practice guidelines to draw firm recommendations regarding the role of hemostatic powder in malignant bleeding.11,28-31 In 2023, a large multicenter RCT, including 106 patients with active GI malignant tumor bleeding (upper or lower), evaluated the efficacy of TC-325 compared with that of conventional endoscopic therapy. This RCT showed that TC-325 achieved significantly higher immediate hemostasis rates (100% vs. 68.6%, p<0.001) than conventional endoscopic treatment.4 The recent individual meta-analysis of three RCTs in 2025 involving 160 patients with malignant GI bleeding robustly confirmed the superior efficacy of TC-325 over conventional endoscopic therapy for immediate hemostasis (98.9% vs. 65.7%; odds ratio [OR], 46.6; 95% confidence interval [CI], 5.89–369.1).11 Moreover, a 2024 meta-analysis revealed that its application showed a significantly lower need for additional non-endoscopic hemostasis compared to conventional therapy (OR, 0.36; 95% CI, 0.15–0.87; p=0.02).10 However, the number of patients included in this meta-analysis was limited. Most studies enrolled fewer than 100 patients. A recent individual patient–level meta-analysis published in 2025,11 which pooled data from three RCTs involving 160 patients with GI bleeding from tumors, strengthens both the quality and robustness of the available evidence. Moreover, conducting RCTs in patients with active tumor-related bleeding is particularly challenging, and future RCTs are unlikely to substantially alter the current conclusions. Additionally, in an RCT by Pittayanon et al.,4 one-third of the patients in the conventional treatment group (31.3%, 16/51) failed therapy, and 93.7% (15/16) of these patients required TC-325 to achieve immediate hemostasis during the same index endoscopy.4 Therefore, we included this high level of evidence to support the use of TC-325 for endoscopic hemostasis in patients with malignant tumor bleeding (Table 1).
Notably, most available evidence regarding the use of hemostatic powder for malignancy-related GI bleeding originates from upper GI tumors and is derived primarily from studies on TC-325, whereas evidence for lower GI malignancies and other hemostatic powders remains limited (Table 1). Therefore, the 2025 Canadian Association of Gastroenterology guidelines conditionally recommend topical hemostatic agents over conventional therapy for active malignant upper GI bleeding with very low certainty due to limited data on only TC-325 hemostatic powder, and the efficacy of other types is still required.2
For rebleeding outcomes, a previous meta-analysis that included 16 studies (14 small observational studies and 2 small RCTs [total n=28]) with 530 patients showed an early rebleeding rate (within 72 hours after endoscopic therapy) of 13.9% (95% CI, 9.7–19.4) and delayed rebleeding rate (after 72 hours after endoscopic therapy) of 11.4% (95% CI, 5.8–21.1).19 However, another RCT showed that none of the patients rebled within 3 days among those in whom immediate hemostasis was achieved.4 Moreover, application of TC-325 hemostatic powder resulted in significantly lower 30-day rebleeding rates than conventional endoscopic treatment (2.1% vs. 21.3%, p=0.003)4; similarly results were observed in a 2025 individual meta-analysis (OR, 0.28; 95% CI, 0.11–0.70).27 The mean time to rebleeding was not statistically longer in the TC-325 group (80.7±69.2 vs. 20.7±11.7 days, p=0.18).4 In contrast, a 2024 meta-analysis found comparable 14- and 30-day rebleeding rates with hemostatic powder (TC-325 and UI-EWD) and conventional therapy for malignant tumor bleeding; however, the results were limited by the wide heterogeneity of bleeding tumor characteristics, including tumor origin and bleeding stigmata. In terms of very long-term rebleeding outcomes, only a small pilot RCT (n=20) also found a trend toward lower 180-day rebleeding rates in the TC-325 group than in the conventional endoscopic treatment group (20% vs. 60%, p=0.17).27
Although most published data on hemostatic powders for malignant bleeding are derived from studies on TC-325, studies on newer agents have also been reported. In a prospective single-arm study of UI-EWD involving 41 patients with upper GI bleeding from malignancy, immediate hemostasis was achieved in 97.5% (40/41), whereas rebleeding within 28 days occurred in 22.5% (10/40) of those who had achieved initial hemostasis.22 A retrospective study reported that EndoClot provided immediate hemostasis (100%, 12/12) for bleeding from gastric malignancy, and 16% (2/12) of the patients rebled in 30 days.32 A small retrospective study of ABS also showed that all patients with malignant bleeding achieved hemostasis (10/10).33
There are still no direct comparative trials focusing on other clinical outcomes, such as the total units of red blood cells transfused after index endoscopy and the length of hospital stay, between hemostatic powder and conventional or non-endoscopic treatments. Two RCTs assessed blood transfusion and length of hospital stay as secondary outcomes and reported no differences between the hemostatic powder and conventional treatment group.4,12
With regard to survival benefit, hemostatic powder therapy alone has not been shown to directly influence short- or long-term survival.10-12,34 Most patients with malignant tumors die from disease progression, with only 13% of deaths attributable to bleeding events4. Previous studies4,21 have identified independent predictors favoring 6-month survival, including good performance status (Eastern Cooperative Oncology Group [ECOG] scores of 0–2), non-end-stage cancer (stages I–III), and receipt of definite oncological treatment. However, as the mean time to first non-endoscopic hemostasis or oncologic treatment is approximately 30 days,4 TC-325 hemostatic powder may provide potential benefits as a bridging therapy, especially for those with good performance status, to enable subsequent non-endoscopic hemostatic treatments targeting the underlying malignancy or definite oncologic treatment.4 Nevertheless, the clinical utility of hemostatic powder in patients with poor performance status (ECOG 3–4) should be individualized.4,12,27
Regarding safety, no luminal or systemic adverse effects of hemostatic powder have been reported in multiple clinical studies on malignant tumor bleeding.4,10,11,26,34,35 However, most available studies involve TC-325, and evidence regarding the safety of other hemostatic powders remains limited. A case of gastric perforation has been reported during attempted hemostasis of diffuse anterior gastric wall bleeding in a patient with post-colectomy ischemic colitis on anticoagulation therapy. The authors described this major adverse event as possibly arising from the force exerted during the release of powder on an apparently inflamed tissue.36
In addition to its efficacy and safety, the feasibility of hemostatic powder, which is attributable to its minimal skill requirement and ready-to-use design, renders it a valuable therapeutic option for treating malignant GI bleeding. The expanding availability of commercial systems has facilitated global adoption, although the high cost of single-use devices may limit accessibility. A recent cost-utility analysis from the United Kingdom demonstrated that hemostatic powder was a cost-saving procedure for GI tumor bleeding compared to conventional endoscopic therapy, primarily by reducing repeat interventions, readmissions, and hospital stay.37 The efficacy, safety, and level of evidence of hemostatic powders in GI malignancy bleeding are shown in Table 1.11,23,32,33
Practical tips and techniques, derived from the authors’ clinical experience, for optimizing hemostatic powder application in GI tumor bleeding can be summarized in several key steps. First, prior to use, air is manually purged through the working channel to eliminate any residual fluid or blood. Second, during catheter insertion, continuous air insufflation through the catheter should be maintained to keep it dry and avoid suction, which could wet the catheter.22 Once the catheter is in place, only air suctioning is allowed during the procedure. Third, positioning the catheter tip approximately 1–2 cm away from the endoscope tip is sufficient. Importantly, during hemostatic powder spraying, the spray catheter should be kept at an adequate distance from the lesion to avoid excessive pressure on the surface and to prevent contact of the catheter with blood. These techniques help minimize the risk of spray catheter occlusion. Fourth, if visualization is obscured by the powder, the lens is promptly washed before further application to ensure efficient coverage. Finally, the treated area should be observed for at least one minute before documenting successful immediate hemostasis as shown in Figures 1 and 2. In our experience, the occlusion of the spray catheter is the main technical issue. The newer NexPowder is designed with a granulation process to reduce catheter clogging during delivery.23,25 However, the data on its efficacy are still warranted.
Hemostatic powder has emerged as a first-line and rescue therapeutic option for malignant GI bleeding. To date, large randomized trials and meta-analyses have consistently demonstrated that TC-325 hemostatic powder application results in higher immediate hemostasis and lower rebleeding rates than conventional endoscopic modalities. Its safety and feasibility are established. Although the survival benefit ultimately depends on definitive oncological therapy, the optimal integration of hemostatic powder as a bridge to subsequent tumor treatment, particularly in patients with good performance status, remains crucial. Data on other types of hemostatic powder are still lacking.
Fig. 1.
Gastroscopy shows diffuse active oozing of blood from gastric tumor invasion with a non-pliable stomach.
ce-2025-387f1.jpg
Fig. 2.
Gastroscopy shows successful hemostasis of gastric malignant tumor bleeding after hemostatic powder application. VDO: Tips and tricks for using Hemospray (Cook Medical).
ce-2025-387f2.jpg
Table 1.
Efficacy, safety, and level of evidence of hemostatic powders in gastrointestinal malignancy bleeding
Hemostatic powder agents Efficacy Safety Level of evidence
Immediate hemostasis rate Rebleeding rate
TC-325 (individual patient data meta-analysis of randomized trials, 2025, n=160)11 98.9% (vs. conventional endoscopic therapy, 65.7%; 95% CI, 5.89–369.1)11 30-Day rebleeding rate, 12.9% (vs. conventional endoscopic therapy, 26.9%; 95% CI, 0.11–0.70)11 No adverse events reported11 High(++++)
UI-EWD (single-arm prospective study, 2021, n=41)23 97.5%23 7-Day rebleeding rate, 7.5%23; 28-day rebleeding rate 22.5%23 No adverse events reported23 Very low(+)
EndoClot polysaccharide hemostatic system (retrospective study, 2018, n=12)32 100%32 30-Day rebleeding rate, 16%32 No adverse events reported32 Very low(+)
Ankaferd Blood Stopper (retrospective study, 2010, n=10)33 100%33 N/A Discoloration of rectal mucosa33, no systemic adverse events reported33 N/A(+/–)

CI, confidence interval; N/A, not applicable.

  • 1. Wuerth BA, Rockey DC. Changing epidemiology of upper gastrointestinal hemorrhage in the last decade: a nationwide analysis. Dig Dis Sci 2018;63:1286–1293.ArticlePubMedPDF
  • 2. Barkun AN, Laine L, Leontiadis GI, et al. Canadian association of gastroenterology clinical practice guideline for the endoscopic management of nonvariceal nonpeptic ulcer upper gastrointestinal bleeding. Gastroenterology 2025;169:863–891.ArticlePubMed
  • 3. Ofosu A, Ramai D, Latson W, et al. Endoscopic management of bleeding gastrointestinal tumors. Ann Gastroenterol 2019;32:346–351.ArticlePubMedPMC
  • 4. Pittayanon R, Khongka W, Linlawan S, et al. hemostatic powder vs standard endoscopic treatment for gastrointestinal tumor bleeding: a multicenter randomized trial. Gastroenterology 2023;165:762–772.ArticlePubMed
  • 5. Poultsides GA, Kim CJ, Orlando R, et al. Angiographic embolization for gastroduodenal hemorrhage: safety, efficacy, and predictors of outcome. Arch Surg 2008;143:457–461.ArticlePubMed
  • 6. Hall T, Temperley HC, Mac Curtain BM, et al. Transcatheter arterial embolisation (TAE) to treat acute upper gastrointestinal bleeding secondary to gastric cancer: a systematic review and meta-analysis. Surgeon 2024;22:e213–e220.ArticlePubMed
  • 7. Asakura H, Hashimoto T, Harada H, et al. Palliative radiotherapy for bleeding from advanced gastric cancer: is a schedule of 30 Gy in 10 fractions adequate? J Cancer Res Clin Oncol 2011;137:125–130.ArticlePubMedPDF
  • 8. Clarke MG, Bunting D, Smart NJ, et al. The surgical management of acute upper gastrointestinal bleeding: a 12-year experience. Int J Surg 2010;8:377–380.ArticlePubMed
  • 9. Abougergi MS, Al-Kawas FH. Topical hemostatic agents for malignancy-related GI bleeding: Is it time to prioritize their use? Gastrointest Endosc 2023;97:209–211.ArticlePubMed
  • 10. Abosheaishaa H, Abdallfatah A, Ahmed OT, et al. The efficacy of Hemospray in managing bleeding related to gastrointestinal tumors: systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2024;36:1370–1383.ArticlePubMed
  • 11. Alali AA, Pittayanon R, Martel M, et al. TC-325 superiority in malignant gastrointestinal bleeding: an individual patient data meta-analysis of randomized trials. Am J Gastroenterol 2025;120:332–339.ArticlePubMed
  • 12. Martins BC, Abnader Machado A, Scomparin RC, et al. TC-325 hemostatic powder in the management of upper gastrointestinal malignant bleeding: a randomized controlled trial. Endosc Int Open 2022;10:E1350–E1357.ArticlePubMedPMC
  • 13. Sheibani S, Kim JJ, Chen B, et al. Natural history of acute upper GI bleeding due to tumours: short-term success and long-term recurrence with or without endoscopic therapy. Aliment Pharmacol Ther 2013;38:144–150.ArticlePubMed
  • 14. Strate LL. Lower GI bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am 2005;34:643–664.ArticlePubMed
  • 15. Schatz RA, Rockey DC. Gastrointestinal bleeding due to gastrointestinal tract malignancy: natural history, management, and outcomes. Dig Dis Sci 2017;62:491–501.ArticlePubMedPDF
  • 16. Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol 2021;116:899–917.ArticlePubMed
  • 17. Shin J, Cha B, Hong J, et al. Prevention of rebleeding after primary haemostasis using haemostatic powder in non-variceal upper gastrointestinal bleeding: a multicentre randomised controlled trial. Gut 2025;74:1821–1827.ArticlePubMed
  • 18. Ibrahim M, El-Mikkawy A, Abdel Hamid M, et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut 2019;68:844–853.ArticlePubMed
  • 19. Karna R, Deliwala S, Ramgopal B, et al. Efficacy of topical hemostatic agents in malignancy-related GI bleeding: a systematic review and meta-analysis. Gastrointest Endosc 2023;97:202–208.ArticlePubMed
  • 20. Pittayanon R, Prueksapanich P, Rerknimitr R. The efficacy of Hemospray in patients with upper gastrointestinal bleeding from tumor. Endosc Int Open 2016;4:E933–E936.ArticlePubMedPMC
  • 21. Pittayanon R, Rerknimitr R, Barkun A. Prognostic factors affecting outcomes in patients with malignant GI bleeding treated with a novel endoscopically delivered hemostatic powder. Gastrointest Endosc 2018;87:994–1002.ArticlePubMed
  • 22. Jiang SX, Chahal D, Ali-Mohamad N, et al. Hemostatic powders for gastrointestinal bleeding: a review of old, new, and emerging agents in a rapidly advancing field. Endosc Int Open 2022;10:E1136–E1146.ArticlePubMedPMC
  • 23. Shin J, Cha B, Park JS, et al. Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding. BMC Gastroenterol 2021;21:40.ArticlePubMedPMCPDF
  • 24. Sung JJ, Luo D, Wu JC, et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011;43:291–295.ArticlePubMed
  • 25. Chen YI, Barkun A, Nolan S. Hemostatic powder TC-325 in the management of upper and lower gastrointestinal bleeding: a two-year experience at a single institution. Endoscopy 2015;47:167–171.ArticlePubMed
  • 26. Chen YI, Barkun AN, Soulellis C, et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc 2012;75:1278–1281.ArticlePubMed
  • 27. Chen YI, Wyse J, Lu Y, et al. TC-325 hemostatic powder versus current standard of care in managing malignant GI bleeding: a pilot randomized clinical trial. Gastrointest Endosc 2020;91:321–328.ArticlePubMed
  • 28. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med 2019;171:805–822.ArticlePubMedPMC
  • 29. Sung JJ, Chiu PW, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut 2018;67:1757–1768.ArticlePubMedPMC
  • 30. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline: update 2021. Endoscopy 2021;53:300–332.ArticlePubMed
  • 31. Mullady DK, Wang AY, Waschke KA. AGA clinical practice update on endoscopic therapies for non-variceal upper gastrointestinal bleeding: expert review. Gastroenterology 2020;159:1120–1128.ArticlePubMed
  • 32. Kim YJ, Park JC, Kim EH, et al. Hemostatic powder application for control of acute upper gastrointestinal bleeding in patients with gastric malignancy. Endosc Int Open 2018;6:E700–E705.ArticlePubMedPMC
  • 33. Kurt M, Akdogan M, Onal IK, et al. Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: a retrospective analysis. Dig Liver Dis 2010;42:196–199.ArticlePubMed
  • 34. Saeed A, Yousuf S, Hayat MH, et al. Comparison of TC-325 hemostatic powder with standard endoscopic treatments for malignancy-related upper gastrointestinal bleeding: meta-analysis of randomized controlled trials. Dig Dis Sci 2024;69:4224–4230.ArticlePubMedPDF
  • 35. Beg S, Al-Bakir I, Bhuva M, et al. Early clinical experience of the safety and efficacy of EndoClot in the management of non-variceal upper gastrointestinal bleeding. Endosc Int Open 2015;3:E605–E609.ArticlePubMedPMC
  • 36. Hagel AF, Albrecht H, Nägel A, et al. The application of Hemospray in gastrointestinal bleeding during emergency endoscopy. Gastroenterol Res Pract 2017;2017:3083481.ArticlePubMedPMCPDF
  • 37. Cooper DM, Norton B, Hawkes ND, et al. Hemostatic powder TC-325 as first-line treatment option for malignant gastrointestinal bleeding: a cost-utility analysis in the United Kingdom. Endoscopy 2025;57:583–592.ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Hemostatic powder for gastrointestinal malignant tumor bleeding
        Close
      • XML DownloadXML Download
      Figure
      • 0
      • 1
      Related articles
      Hemostatic powder for gastrointestinal malignant tumor bleeding
      Image Image
      Fig. 1. Gastroscopy shows diffuse active oozing of blood from gastric tumor invasion with a non-pliable stomach.
      Fig. 2. Gastroscopy shows successful hemostasis of gastric malignant tumor bleeding after hemostatic powder application. VDO: Tips and tricks for using Hemospray (Cook Medical).
      Hemostatic powder for gastrointestinal malignant tumor bleeding
      Hemostatic powder agents Efficacy Safety Level of evidence
      Immediate hemostasis rate Rebleeding rate
      TC-325 (individual patient data meta-analysis of randomized trials, 2025, n=160)11 98.9% (vs. conventional endoscopic therapy, 65.7%; 95% CI, 5.89–369.1)11 30-Day rebleeding rate, 12.9% (vs. conventional endoscopic therapy, 26.9%; 95% CI, 0.11–0.70)11 No adverse events reported11 High(++++)
      UI-EWD (single-arm prospective study, 2021, n=41)23 97.5%23 7-Day rebleeding rate, 7.5%23; 28-day rebleeding rate 22.5%23 No adverse events reported23 Very low(+)
      EndoClot polysaccharide hemostatic system (retrospective study, 2018, n=12)32 100%32 30-Day rebleeding rate, 16%32 No adverse events reported32 Very low(+)
      Ankaferd Blood Stopper (retrospective study, 2010, n=10)33 100%33 N/A Discoloration of rectal mucosa33, no systemic adverse events reported33 N/A(+/–)
      Table 1. Efficacy, safety, and level of evidence of hemostatic powders in gastrointestinal malignancy bleeding

      CI, confidence interval; N/A, not applicable.


      Clin Endosc : Clinical Endoscopy Twitter Facebook
      Close layer
      TOP